CROSSROADS-2: Clinical Characteristics, Treatment Patterns, and Treatment Outcomes Among Users of Tezspire: An Electronic Medical Record (EMR) study (20220066)

Study identification

• EU PAS number:
  EUPAS1000000053
• Study ID:
  1000000053
• Official title and acronym:
  CROSSROADS-2: Clinical Characteristics, Treatment Patterns, and Treatment Outcomes Among Users of Tezspire: An Electronic Medical Record (EMR) study (20220066)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  Retrospective cohort study to describe the characteristics of patients treated with Tezspire (tezepelumab-ekko) in the real-world setting. ; Additionally, this study will describe treatment patterns and asthma related clinical outcomes of patients initiating Tezspire. ; Tezspire patients will be identified in the TriNetX Dataworks-USA network (a de-identified, longitudinal Electronic Medical Record (EMR)-derived dataset that includes outpatient and inpatient EMRs from 60 healthcare organizations (HCOs) across the US).
• Study status:
  Ongoing

Research institutions and networks

Institutions

Amgen

United States

Study timelines

Date when funding contract was signed

Planned: 07/11/2022

Actual: 07/11/2022

Study start date

Planned: 18/01/2024

Actual: 18/01/2024

Data analysis start date

Planned: 15/07/2025

Date of final study report

Planned: 01/02/2026

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen 100%

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

20220066